AIDS TREATMENT NEWS #343, May 19, 2000
John S. James
From the abstract: "Conclusions: Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings. Resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women. It should be considered in treatment- naive patients with established infection, but cannot be firmly recommended in this setting. Testing also should be considered prior to initiating therapy in patients with acute HIV infection, although therapy should not be delayed pending the results. Expert interpretation is recommended given the complexity of results and assay limitations."
Besides the value of the recommendations themselves, this paper is important as the most authoritative review on resistance testing at this time (although it will probably become obsolete later this year). It discusses the different tests, and the many complexities around their use. It includes a chart showing the major resistance mutations for all 14 of the currently approved antiretrovirals. It reviews the current state of knowledge of resistance testing through April 2000, with 94 references to major publications on HIV drug resistance.
Also see the editorial(2) on resistance testing in the same issue.
Note: The U.S. Health and Human Services guidelines, updated January 28, also recommend resistance testing in some circumstances--but are much less detailed than those of the new IAS guidelines. The HHS guidelines are available at http://www.hivatis.org/trtgdlns.html
References
1. Hirsch MS, Brun-Vezinet F, D'Aquila RT and others. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-- USA Panel. JAMA. May 10, 2000; volume 283, number 18, pages 2417-2426. This document, and the editorial below, are available at the JAMA HIV page, http://www.ama-assn.org/special/hiv/
2. Flexner, C. HIV Genotype and Phenotype--Arresting Resistance? JAMA. May 10, 2000; volume 283, number 18, pages 2442-2444.
000519
ATN34303
Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .